ArticleOpen forum infectious diseases2026
Outcome of and Risk Factors for Mortality in Pediatric Coronavirus Disease 2019 Encephalitis During the 2022 Omicron Wave in Taiwan: A National Retrospective Study.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During Taiwan's severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron outbreak in 2022, pediatric coronavirus disease 2019 (COVID-19) encephalitis cases surged, resulting in multiple fatalities. We investigated patient characteristics and mortality risk factors. Method: Using the Brighton Collaboration criteria, we identified 289 suspected pediatric COVID-19 encephalitis cases diagnosed between April and December 2022 by linking the national surveillance, remdesivir application, immunization, and death registries. We analyzed clinical data and viral genotypes, then used univariate and multivariate logistic regressions to assess mortality risk factors. Results: We identified 75 encephalitis cases: 50 (67%) were male, with a median age of 5 years (interquartile range [IQR]: 3-8 years), 45 (60%) had no comorbidities, and 23 (31%) had received at least 1 dose of the COVID-19 vaccine. The median interval from symptom onset to medical attention was <1 day (IQR: 0-1 day).Fourteen cases (19%) died after a median hospital stay of 3 days (IQR: 1-5 days). All sequenced viruses matched the circulating Omicron subvariants. In univariate analysis, age <5 years was associated with increased mortality (odds ratio [OR] & 6.05; 95% confidence interval [CI] & 1.53-24.00). Multivariate analysis showed a nonsignificant trend (adjusted OR & 3.64; 95% CI & 0.81-16.40) after adjustment for sex, comorbidities, and vaccination. Conclusions: During the Omicron wave, the number of pediatric COVID-19 encephalitis cases progressed rapidly and mortality was high, particularly among children <5 years of age, regardless of comorbidities. We recommend COVID-19 vaccination and monitoring for signs of COVID-19 encephalitis in young children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.